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Bipolar disorder (manic-depressive illness) is a chronic
episodic disorder with a lifetime prevalence of 0.8–1.6%
[1–3]. Almost all patients with acute mania require rapid,
effective treatment and hospitalization. The primary goal of
treatment is to keep patients safe and to limit the economic,
social, and personal costs of manic episodes. Monotherapy
with mood stabilizers is still used as a first-line therapy and
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is efficacious for the treatment of acute mania, but there is
a delay in therapeutic onset of 1–2 weeks [4–8].
Because rapid control of acute mania is desired,
adjunctive agents, including antipsychotics, clonazepam,
lorazepam, verapamil, nimodipine, clonidine, and
levothyroxine, are widely used [5,9–12]. Surveys of treatment
practices for acute mania suggest that up to 90% of patients
with acute mania are treated with a combination of mood
stabilizers and antipsychotics [6,13–15]. Typical
antipsychotics may produce undesirable side effects, such
as induction of depressive symptoms, neuroleptic-induced
dystonia, akathisia, extrapyramidal side effects (EPS),
and a long-term risk of tardive dyskinesia (TD) [16,17].
These side effects occur more frequently in patients with
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affective disorders than in schizophrenics exposed to typical
antipsychotic treatment. Atypical antipsychotics are
generally better tolerated than typical antipsychotics because
of the decreased risk of EPS and TD [6,18].
Most research regarding the use of antipsychotic drugs
in the treatment of acute mania has focused on the safety,
efficacy, and adverse effects of these drugs. To date, few
studies have directly compared atypical antipsychotics with
typical antipsychotics as adjunctive therapy in inpatient
treatment of acute mania [19,20]. In our retrospective and
paired-subject comparison study, we provide a controlled
comparison of risperidone and typical antipsychotics in the
treatment of acute mania.
MATERIALS AND METHODS
Patients
In this retrospective, case-controlled chart review, we
surveyed the charts of inpatient units of Kaohsiung
Medical University Chung-Ho Memorial (KMU) Hospital
between July 1, 1999, and December 31, 2003. Patients
with histories of bipolar I disorder with a Diagnostic and
Statistical Manual of Mental Disorders, 4th edition
(DSM-IV)-defined diagnosis and at least two prior manic
episodes were included in the study. Exclusion criteria
included the presence of other psychotic disorders,
substance abuse or dependence, and seizure disorders.
Gender, age, number of prior admissions, and duration
of illness were controlled.
During the study period, 146 patients who had bipolar
I disorder (current episode, mania), were admitted to the
acute psychotic ward of KMU Hospital. Of these, 39 patients
had been treated with risperidone, in addition to mood
stabilizers. Seven patients were excluded because they were
discharged against advice. This study included 32 cases in
which risperidone was used as adjunctive therapy
(risperidone group). The control group comprised other
cases in which typical antipsychotics (chlorpromazine,
haloperidol, sulpiride [21], clotiapine, or thioridazine) were
used as adjunctive therapy. Data that were equivocal or
unavailable were excluded on a case-by-case basis.
Medications were prescribed independently by the treating
psychiatrists. All medications used during hospitalization
were recorded. All patients were taking mood stabilizers.
Assessment
Length of hospital stay, adverse effects, Global Assessment
of Functioning (GAF) [22] score at discharge, and Clinical
Global Impression-Improvement (CGI-I) [23] score at
discharge were compared between groups. At the time of
discharge, the GAF and CGI-I scores were rated by the
psychiatrist responsible for treatment during admission.
The comparisons included frequency of drug use, type
of drug prescribed, average dosages during hospitalization
and discharge dosages. Dosages of all antipsychotics,
including risperidone, were converted to approximate
chlorpromazine (CPZe)-equivalent mg/day doses [24].
The serum concentrations of mood stabilizers were
compared using the last possible steady-state level.
Drug adverse effects included EPS, tremor, and over-
sedation. EPS included neuroleptic-induced parkin-
sonism, neuroleptic-induced dystonia, neuroleptic-induced
akathisia, and TD. The presence or absence of drug adverse
effects was recorded. If patients needed to take
anticholinergics for drug adverse effects, the individual
psychiatrist prescribed trihexyphenidyl.
Analyses
All statistical analyses were performed with the Statistical
Package for the Social Sciences (SPSS) for Windows (SPSS
Inc., Chicago, IL, USA) and included analysis of variance
for between-group comparisons, the Kruskal-Wallis test,
the Mann-Whitney test, and appropriate post hoc tests.
RESULTS
Demographic data and severity of illness
There were no significant differences between groups
in gender (Kruskal-Wallis r2 = 0.000, df = 1, p = 1.0),
age (Mann-Whitney U = 506.5, Z = –0.074, p = 0.941),
duration of illness (Mann-Whitney U = 509.0, Z = –0.040,
p = 0.968), and number of prior admissions (Mann-Whitney
U = 434.0, Z = –1.105, p = 0.269) (Table 1).
Improvement at discharge
Patients in both groups were less severely ill at discharge
than at admission. The differences in GAF scores (Mann-
Whitney U = 481.0, Z = –0.436, p = 0.663) and CGI-I scores
(post hoc analysis, Kruskal-Wallis r2 = 0.007, df = 1, p = 0.932)
at discharge were not statistically significant between
groups (Table 2).
Adverse drug effects and trihexyphenidyl
In terms of adverse drug effects, there was no significant
difference between patients treated with typical
antipsychotics and those treated with risperidone (Kruskal-
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Wallis r2 = 1.371, df = 1, p = 0.242). In the risperidone group,
11 patients (34.4%) were treated with trihexyphenidyl and
21 (65.6%) were not. In the control group, 13 patients
(40.6%) received trihexyphenidyl and 19 (59.4%) did not.
The mean dosage of trihexyphenidyl was significantly lower
in the risperidone group (1.6 mg/day) than in the control
group (3.0 mg/day; Mann-Whitney U = 374.5, Z = –2.020,
p = 0.043) (Table 2).
Medications
There was no statistical difference in CPZe equivalent doses
between the risperidone and control groups (Mann-Whitney
U = 466.0, Z = –0.620, p = 0.535). The average dosage of
risperidone was 2.67 mg/day. There was no significant
difference between groups in the use of single or multiple
mood stabilizers (Kruskal-Wallis r2 = 0.680, df = 1, p = 0.410).
In the risperidone group, 17 patients (53.1%) were treated
with only lithium as a mood stabilizer. The mean plasma
concentration of lithium was 0.63 mEq/L (12 hours after
last dose). In the control group, 21 patients (65.6%) were
treated with only lithium as a mood stabilizer. The mean
plasma concentration of lithium was 0.67 mEq/L. The
clonazepam doses during hospitalization were lower in the
risperidone group than in the control group, although this
difference was not significant (Mann-Whitney U = 482.0,
Z = –0.445, p = 0.656) (Table 3).
Length of hospital stay
The mean hospital stay was 22.4 days in the risperidone
group and 32.5 days in the control group. Post hoc testing
showed that patients treated with risperidone had a
significantly shorter hospital stay than those treated with
typical antipsychotics (Mann-Whitney U = 309.0, Z = –2.728,
p = 0.006).
Table 1. Demographic characteristics and clinical severity
Characteristics Control group (n = 32) Risperidone group (n = 32) p
Age (yrs)* 40.2 (  14.2 40.4 ( 14.2 0.941
Gender 1
Female 21 (65.6%) 21 (65.6%)
Male 11 (34.4%) 11 (34.4%)
Duration of illness (yrs)* 8.5 ( 7.9 9.4 ( 9.8 0.968
Prior admissions (yrs)* 2.8 ( 3.1 3.5 ( 3.2 0.269
*Mean ( standard deviation.
Table 2. Outcome at discharge, drug adverse effects, and anticholinergics
Variable Control group (n = 32) Risperidone group (n = 32) p
GAF score at discharge* 55.6 (  11.3 57.5 ( 9.5 0.663
CGI-I score at discharge 0.932
Much improved 21 (65.6%) 22 (68.8%)
Mildly improved 11 (34.4%) 10 (31.2%)
Adverse effect 0.242
Present 20 (62.5%) 18 (56.3%)
Absent 12 (37.5%) 14 (43.7%)
Trihexyphenidyl 0.043
Not taking 13 (40.6%) 21 (65.6%)
Taking 19 (59.4%) 11 (34.4%)
Dose (mg/day)* 3.0 ( 2.9 1.6 ( 2.3
*Mean ( standard deviation. GAF = Global Assesment of Functioning; CGI-I = Clinical Global Impression-Improvement.
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Table 3. Comparison of medications and dosages between groups
Variable Control group (n = 32) Risperidone group (n = 32) p
Equivalence to CPZe dose (mg/day)* 203.3 ( 149.5 178.1 ( 102.9 0.535
Mood stabilizers 0.41
Single 24 (75.0%) 22 (68.8%)
Multiple 8 (25.0%) 10 (31.2%)
Clonazepam 0.656
Not taking 18 (56.3%) 18 (56.3%)
Taking 14 (43.7%) 14 (43.7%)
Dose (mg/day)* 1.5 ( 2.9 0.8 ( 1.2
Plasma lithium concentrations
Only lithium 21 (65.6%) 17 (53.1%)
Mean (mEq/L) 0.67 0.63
*Mean ( standard deviation. CPZe = chlorpromazine.
DISCUSSION
This case-controlled study compared the combination of
mood stabilizers with either risperidone or typical
antipsychotics in the treatment of acute mania in a clinical
environment. This study analyzed treatment effects in
patients routinely seen in clinical practice; treatment was
based on clinical judgment rather than on a fixed protocol
and all medications were monitored in detail. Case and
control patients were carefully matched on gender, age,
duration of illness, and number of prior admissions;
each dose of medication, including mood stabilizers and
antipsychotics, represent a good reference of clinical
practice. The limitations were as follows: the subject
numbers were relatively small, so there may have been a
false-negative effect in group comparisons; the attending
physicians who made judgments regarding medication
dosing were not blinded to the medications given; only
clinical global impressions were used as treatment outcome
measures; and adverse effects of medications were reported
by clinical description rather than assessed using systematic
rating scales. However, we believe that this report reflects
the conditions in a real clinical setting, and, hence, it
deserves further discussion.
Given these limitations, the study yields interesting
results. The clinical improvement at discharge was not
significantly different between groups, although patients
treated with risperidone had a shorter hospital stay than
those treated with typical antipsychotics. In the current
managed-care system, decreasing hospital stay is a welcome
benefit. The mean serum levels of lithium in this study were
0.63 and 0.67 mEq/L in the risperidone and typical
antipsychotic groups, respectively. Several studies,
including this one, have suggested that these levels are
within the most common guideline for monotherapy main-
tenance therapeutic ranges [10,25,26]. The average dosage
of risperidone during this admission was 2.67 mg/day,
which is lower than the therapeutic dosage for acute
exacerbations of schizophrenia (4–6 mg/day) [27]. Recent
data support that, in the treatment of acute mania, atypical
antipsychotics have a lower incidence of adverse effects
than typical antipsychotics. Although there was no
quantitative systemic assessment supporting a significant
difference in adverse drug effects between the two groups,
patients treated with risperidone received lower
anticholinergic doses than those treated with typical
antipsychotics (given according to the attending physician’s
judgment).
In conclusion, this chart review demonstrates that
risperidone may lead to decreased hospital stay when used
with mood stabilizers to treat manic episodes. Risperidone,
in particular, decreases the need for anticholinergics and
may be more effective than the typical antipsychotics.
ACKNOWLEDGMENTS
The authors thank Chang Shun Jen, PhD, Department of
Public Health, Kaohsiung Medical University, for analyzing
the data.
Antipsychotics in acute mania
Kaohsiung J Med Sci December 2005 • Vol 21 • No 12 543
REFERENCES
1. Regier DA, Myers JK, Kramer M, et al. The NIMH
epidemiologic catchment area program: historical context,
major objectives, and study population characteristics. Arch
Gen Psychiatry 1984;41:934–41.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-
month prevalence of DSM-III-R psychiatric disorders in the
United States: results from the National Comorbidity Survey.
Arch Gen Psychiatry 1994;51:8–19.
3. Tohen M, Goodwin FK. Epidemiology of bipolar disorder. In:
Tsuang MT, Tohen M, Zahner G, eds. Psychiatric Epidemiology.
New York: John Wiley & Sons, 1995:301–16.
4. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The
treatment of manic psychoses by the administration of lithium
salt. J Neurol Neurosurg Psychiatry 1954;17:250–60.
5. Goodwin FK, Murphy DL, Bunney WE. Lithium carbonate
treatment in depression and mania: a longitudinal double-
blind study. Arch Gen Psychiatry 1969;21:486–96.
6. Prien RF, Caffey EM, Klett CJ. A comparison of lithium
carbonate and chlorpromazine in the treatment of acute mania.
Arch Gen Psychiatry 1972;26:146–53.
7. Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy
of lithium carbonate and chlorpromazine in mania. Arch Gen
Psychiatry 1975;32:1310–8.
8. American Psychiatric Association. Practice guideline for the
treatment of patients with bipolar disorder. Am J Psychiatry
1994;151:1–36.
9. Freeman MP, Stoll AL. Mood stabilizer combinations: a review
of safety and efficacy. Am J Psychiatry 1998;155:12–21.
10. Sadock BJ, Sadock VA. Major depression and bipolar disorder.
In: Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/
Clinical Psychiatry, 9th edition. Philadelphia: Lippincott
Williams & Wilkins, 2003:570–1.
11. Bodkin JA. Emerging uses for high-potency benzodiazepines
in psychotic disorders. J Clin Psychiatry 1990;51:41–6.
12. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM.
Adjunctive treatment of manic agitation with lorazepam versus
haloperidol: a double-blind study. J Clin Psychiatry 1992;53:
47–52.
13. Sernyak MJ, Griffin RA, Johnson RM, et al. Neuroleptic
exposure following inpatient treatment of acute mania with
lithium and neuroleptic. Am J Psychiatry 1994;151:133–5.
14. Keck PE, McElroy SL, Strakowski SM, et al. Factors associated
with maintenance antipsychotic treatment of patients with
bipolar disorder. J Clin Psychiatry 1996;57:147–51.
15. Zarate CA, Tohen M. Antipsychotic drug treatment in first-
episode mania: a 6-month longitudinal study. J Clin Psychiatry
2000;61:33–8.
16. Kukopulos A, Reginadi D, Laddomada P, et al. Course of the
manic-depressive cycle and changes caused by treatment.
Pharmakopsychiatr Neuropsychopharmakol 1980;13:156–67.
17. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: a Task
Force Report of the American Psychiatric Association. Washington,
DC: American Psychiatric Press, 1992.
18. Ghaemi SN, Goodwin FK. Use of atypical agents in bipolar
and schizoaffective disorders: review of the empirical
literature. J Clin Psychiatry 1999;19:354–61.
19. Miller DS, Yatham LN, Lam RW. Comparative efficacy of
typical and atypical antipsychotics as add-on therapy to mood
stabilizers in the treatment of acute mania. J Clin Psychiatry
2001;62:975–80.
20. Alder L, Ulrich M, Lehmann K, et al. Acute inpatient treatment
of manias. Effects of independent variables on neuroleptic
dosage and length of stay. Nervenarzt 1996;67:235–43.
21. Sadock BJ, Sadock VA. Dopamine receptor antagonist: typical
antipsychotics. In: Kaplan & Sadock’s Synopsis of Psychiatry:
Behavioral Sciences/Clinical Psychiatry, 9th edition. Philadelphia:
Lippincott Williams & Wilkins, 2003:1050–67.
22. Luborsky L. Clinicians’ judgments of mental health. Arch Gen
Psychiatry 1962;7:407–17.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology.
US Dept of Health, Education, and Welfare publication (ADM)
76-338. Rockville, MD: National Institute of Mental Health,
1976:218–22.
24. Bazire S. Selecting drugs, doses and preparations: switching
drugs. In: Bazire S, ed. Psychotropic Drug Directory 2003/04.
Salisbury: Fivepin Publishing, 2003:179–80.
25. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of
divalproex vs lithium and placebo in the treatment of mania.
The Depakote Mania Study Group. JAMA 1994;271:918–24.
26. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a
mood stabilizer with risperidone or haloperidol for treatment
of acute mania: a double-blind, placebo-controlled comparison
of efficacy and safety. Am J Psychiatry 2002;159:1146–54.
27. Lane HY, Chiu WC, Chou JCY, et al. Risperidone in acute
exacerbated schizophrenia: dosing strategies and plasma
levels. J Clin Psychiatry 2000;61:209–14.
544 Kaohsiung J Med Sci December 2005 • Vol 21 • No 12
